Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
This study is currently recruiting participants.
Study NCT00703638 Information provided by National Cancer Institute (NCI)
First Received: June 20, 2008 Last Updated: June 16, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Malignant Mesothelioma
Pancreatic Cancer
Prostate Cancer
Sarcoma
Additional conditions recognized in this trial
Breast Neoplasms
Colorectal Neoplasms
Head and Neck Neoplasms
Lung Neoplasms
Mesothelioma
Pancreatic Neoplasms
Prostatic Neoplasms
More general conditions related to this trial
Adenoma
Breast Diseases
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Intestinal Diseases
Intestinal Neoplasms
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Pancreatic Diseases
Prostatic Diseases
Rectal Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Interventions listed in this trial
cisplatin
pemetrexed disodium
sorafenib tosylate
Additional drug interventions recognized in this trial
Pemetrexed
Sorafenib
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Back to top of Main Content
